Evidence map›Paper›PMID 41919248›Full record

ArticleFrontiers in oncology2026

Daniel Martínez Anaya, Liliana Fernández Hernández, Marian Valladares Coyotecatl, Ulises Juárez Figueroa, Michael Dean, Luis Juárez Villegas, Marta Zapata Tarrés, Norma López Santiago, Patricia Pérez-Vera

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel Martínez AnayaLaboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico.
Liliana Fernández HernándezLaboratorio de Biología Molecular, Instituto Nacional de Pediatría, Mexico City, Mexico.
Marian Valladares CoyotecatlLaboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico.
Ulises Juárez FigueroaLaboratorio de Citogenética, Instituto Nacional de Pediatría, Mexico City, Mexico.
Michael DeanLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.
Luis Juárez VillegasServicio de Hemato-Oncología, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Marta Zapata TarrésComisión Coordinadora de Institutos Nacionales de Salud y Hospitales de Alta Especialidad, Mexico City, Mexico.
Norma López SantiagoServicio de Hematología, Instituto Nacional de Pediatría, Mexico City, Mexico.
Patricia Pérez-VeraLaboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Deleterious Aim: To describe the mutational profile of Methods: Next-generation exome sequencing was performed on 73 Mexican children with pre-B ALL. Clinical and genetic features of Results: Conclusions: Our findings and those described in the literature suggest that

Indexed as

B-cell precursor acute lymphoblastic leukemiacancer predispositionCHEK2 germline variantsCHEK2 p.Leu236Progermline predispositionMexican pediatric patients

Identifiers

PMID41919248
PMCPMC13034570

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.